Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure

Molecular Pharmacology

Volumn 76, Issue 3, 2009, Pages 466-480

  Dorn II, Gerald W ^a   Liggett, Stephen B ^b,c  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c HSF II   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DOBUTAMINE; ISOPRENALINE; METOPROLOL; MOXONIDINE; PLACEBO; PROPRANOLOL;

ADRENERGIC SYSTEM; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART MUSCLE CELL; HUMAN; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

ADRENERGIC BETA-ANTAGONISTS; AMINO ACID SEQUENCE; ANIMALS; CHRONIC DISEASE; G-PROTEIN-COUPLED RECEPTOR KINASE 5; GENETIC VARIATION; HEART FAILURE; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-1;

EID: 69549106507     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.056572     Document Type: Short Survey

References (61)

1. Benovic JL, DeBlasi A, Stone WC, Caron MG, and Lefkowitz RJ (1989) etaadrenergic receptor kinase: primary structure delineates a multigene family. Science 246:235-240. (Pubitemid 19264636)
2. Benovic JL, Mayor F Jr, Staniszewski C, Lefkowitz RJ, and Caron MG (1987) Purification and characterization of beta-adrenergic receptor kinase. J Biol Chem 262:9026-9032.
3. Benovic JL, Strasser RH, Caron MG, and Lefkowitz RJ (1986) Beta-adrenergic receptor kinase: identification of a novel protein kinase phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci U S A 83:2797-2801.
4. BEST Trial Investigators (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:1659-1667. (Pubitemid 32479963)
5. Bristow M (2003) Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 107:1100-1102. (Pubitemid 36297198)
6. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, Cates AE, and Feldman AM (1990) Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 82:I12-I25. (Pubitemid 20245291)
7. Brodde OE (2007) Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 374:361-372.
8. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, and Brodde OE (2005) The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 46:2111-2115. (Pubitemid 41713600)
9. Chen EP, Bittner HB, Akhter SA, Koch WJ, and Davis RD (2001) Myocardial function in hearts with transgenic overexpression of the G protein-coupled receptor kinase 5. Ann Thorac Surg 71:1320-1324. (Pubitemid 32328697)
10. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, and Wright TJ (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659-667. (Pubitemid 38043972)
11. de Groote P, Lamblin N, Helbecque N, Mouquet F, Mc Fadden E, Hermant X, Amouyel P, Dallongeville J, and Bauters C (2005) The impact of beta-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure. Eur J Heart Fail 7:966-973. (Pubitemid 41443589)
12. DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510.
13. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, Arnold K, Ruano G, and Liggett SB (2000) Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 97:10483-10488. (Pubitemid 30707292)
14. Fauchier L, Pierre B, de Labriolle A, and Babuty D (2007) Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur J Heart Fail 9:1136-1139. (Pubitemid 47633317)
15. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
16. Freeman JL, De La Cruz EM, Pollard TD, Lefkowitz RJ, and Pitcher JA (1998) Regulation of G protein-coupled receptor kinase 5 (GRK5) by actin. J Biol Chem 273:20653-20657. (Pubitemid 28377637)
17. Gerson MC, Wagoner LE, McGuire N, and Liggett SB (2003) Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor. J Nucl Cardiol 10:583-589. (Pubitemid 38035392)
18. Gilsbach R, Brede M, Beetz N, Moura E, Muthig V, Gerstner C, Barreto F, Neubauer S, Vieira-Coelho MA, and Hein L (2007) Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction. Cardiovasc Res 75:728-737. (Pubitemid 47238738)
19. Hata JA, Williams ML, and Koch WJ (2004) Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization. J Mol Cell Cardiol 37:11-21.
20. Hein L, Altman JD, and Kobilka BK (1999) Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402:181-184.
21. Joseph SS, Lynham JA, Grace AA, Colledge WH, and Kaumann AJ (2004) Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br J Pharmacol 142:51-56.
22. Kunapuli P and Benovic JL (1993) Cloning and expression of GRK5: a member of the G protein-coupled receptor kinase family. Proc Natl Acad Sci U S A 90:5588-5592. (Pubitemid 23176206)
23. Leineweber K, Bruck H, Temme T, Heusch G, Philipp T, and Brodde OE (2006) The Arg389Gly beta1-adrenoceptor polymorphism does not affect cardiac effects of exercise after parasympathetic inhibition by atropine. Pharmacogenet Genomics 16:9-13. (Pubitemid 41803872)
24. Levin MC, Marullo S, Muntaner O, Andersson B, and Magnusson Y (2002) The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 277:30429-30435. (Pubitemid 34970733)
25. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, Diwan A, Martini JS, Sparks L, Parekh RR, et al. (2008) A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 14:510-517. (Pubitemid 351655214)
26. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103:11288-11293. (Pubitemid 44156511)
27. Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Schofield RS, Hamilton KK, Herbert Patterson J, Adams KF Jr., et al. (2007) Synergistic polymorphisms of beta1 and alpha2c-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 17:277-282. (Pubitemid 46668051)
28. Mann DL and Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111:2837-2849. (Pubitemid 40791557)
29. Mason DA, Moore JD, Green SA, and Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670-12674. (Pubitemid 129518037)
30. Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley AM, Brunskill EW, Koch WJ, Schwartz RJ, and Dorn GW 2nd (2006) Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res 99:996-1003.
31. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007. (Pubitemid 29271744)
32. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, and Liggett SB (2003) B1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300-1305. (Pubitemid 37279854)
33. Molenaar P, Chen L, Semmler AB, Parsonage WA, and Kaumann AJ (2007) Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism. Clin Exp Pharmacol Physiol 34:1020-1028. (Pubitemid 47274562)
34. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, and Shusterman NH (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355.
35. Pitcher JA, Freedman NJ, and Lefkowitz RJ (1998) G protein-coupled receptor kinases. Annu Rev Biochem 67:653-692.
36. Premont RT, Inglese J, and Lefkowitz RJ (1995) Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J 9:175-182.
37. Premont RT, Koch WJ, Inglese J, and Lefkowitz RJ (1994) Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J Biol Chem 269:6832-6841. (Pubitemid 24191077)
38. Pronin AN, Satpaev DK, Slepak VZ, and Benovic JL (1997) Regulation of G protein-coupled receptor kinases by calmodulin and localization of the calmodulin binding domain. J Biol Chem 272:18273-18280. (Pubitemid 27306417)
39. Rathz DA, Brown KM, Kramer LA, and Liggett SB (2002) Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39:155-160.
40. Rathz DA, Gregory KN, Fang Y, Brown KM, and Liggett SB (2003) Hierarchy of polymorphic variation and desensitization permutations relative to beta 1- and beta 2-adrenergic receptor signaling. J Biol Chem 278:10784-10789. (Pubitemid 36800351)
41. Rochais F, Vilardaga JP, Nikolaev VO, Bünemann M, Lohse MJ, and Engelhardt S (2007) Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest 117:229-235. (Pubitemid 46048469)
42. Sallese M, Iacovelli L, Cumashi A, Capobianco L, Cuomo L, and De Blasi A (2000) Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins. Biochim Biophys Acta 1498:112-121.
43. Sandilands AJ, Parameshwar J, Large S, Brown MJ, and O'Shaughnessy KM (2005) Confirmation of a role for the 389R>G beta-1 adrenoceptor polymorphism on exercise capacity in heart failure. Heart 91:1613-1614. (Pubitemid 41697613)
44. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, Muhlestein JB, Donahue M, Liggett SB, Anderson JL, et al. (2008) Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol and metoprolol. J Am Coll Cardiol 52:644-651.
45. Shin J, Lobmeyer MT, Gong Y, Zineh I, Langaee TY, Yarandi H, Schofield RS, Aranda JM Jr, Hill JA, Pauly DF, et al. (2007) Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol 99:250-255. (Pubitemid 46072763)
46. Small KM, Brown KM, Seman CA, Theiss CT, and Liggett SB (2006) Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression. Proc Natl Acad Sci U S A 103:5472-5477.
47. Small KM, Forbes SL, Rahman FF, Bridges KM, and Liggett SB (2000) A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275:23059-23064.
48. Small KM, Mialet-Perez J, and Liggett SB (2008) Genetic variation within the beta1-adrenergic receptor gene results in haplotype-specific expression phenotypes. J Cardiovasc Pharmacol 51:106-110.
49. Small KM, Mialet-Perez J, Seman CA, Theiss CT, Brown KM, and Liggett SB (2004) Polymorphisms of the cardiac presynaptic alpha2C adrenergic receptors: diverse intragenic variability with haplotype-specific functional effects. Proc Natl Acad Sci U S A 101:13020-13025. (Pubitemid 39167576)
50. Small KM, Tanguay DA, Nandabalan K, Zhan P, Stephens JC, and Liggett SB (2003) Gene and protein domain-specific patterns of genetic variability within the G-protein coupled receptor superfamily. Am J Pharmacogenomics 3:65-71. (Pubitemid 36307063)
51. Small KM, Wagoner LE, Levin AM, Kardia SL, and Liggett SB (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135-1142.
52. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, Jiang R, Messer CJ, Chew A, Han JH, et al. (2001) Haplotype variation and linkage disequilibrium in 313 human genes. Science 293:489-493. (Pubitemid 32679076)
53. Swift SM, Gaume BR, Small KM, Aronow BJ, and Liggett SB (2008) Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs. Physiol Genomics 35:123-131.
54. Swift SM, Schwarb MR, Mihlbachler KA, and Liggett SB (2007) Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol 36:236-243.
55. Tepe NM, Lorenz JN, Yatani A, Dash R, Kranias EG, Dorn GW2 and Liggett SB (1999) Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte B-adrenergic signalling. Biochem 38:16706-16713. (Pubitemid 30007525)
56. Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hamilton KK, Aranda JM, Hill JA, et al. (2005) beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 77:127-137.
57. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, and Liggett SB (1996) Myocardial signalling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 93:10483-10488. (Pubitemid 26314649)
58. van Campen LC, Visser FC, and Visser CA (1998) Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol 32 (Suppl 1):S31-S35.
59. Wagoner LE, Craft LL, Zengel P, McGuire N, Rathz DA, Dorn GW 2nd, and Liggett SB (2002) Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 144:840-846.
60. Wang WC, Mihlbachler KA, Bleecker ER, Weiss ST, and Liggett SB (2008) A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genomics 18:729-732.
61. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, Ball SG, Hall AS, and Balmforth AJ (2003) An evaluation of the beta-1-adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5:463-468. (Pubitemid 37021640)